These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12608543)

  • 21. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
    Pizzi LT; Talati A; Gemmen E; Dahl NV; Bunz TJ; Sand PK
    Pharmacoeconomics; 2009; 27(4):329-39. PubMed ID: 19485428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
    Sathyan G; Dmochowski RR; Appell RA; Guo C; Gupta SK
    Clin Pharmacokinet; 2004; 43(14):1059-68. PubMed ID: 15530134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
    Dmochowski RR; Nitti V; Staskin D; Luber K; Appell R; Davila GW
    World J Urol; 2005 Sep; 23(4):263-70. PubMed ID: 16151816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males.
    Chik Z; Johnston A; Tucker AT; Chew SL; Michaels L; Alam CA
    Br J Clin Pharmacol; 2006 Mar; 61(3):275-9. PubMed ID: 16487220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids.
    Lukkari E; Hakonen T; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Jan; 53(5):351-4. PubMed ID: 9516036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.
    Mizushima H; Kinoshita K; Abe K; Ishizuka H; Yamada Y
    Biol Pharm Bull; 2007 May; 30(5):955-62. PubMed ID: 17473442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enantioselective analysis of oxybutynin and N-desethyloxybutynin with application to an in vitro biotransformation study.
    da Fonseca P; de Freitas LA; Pinto LF; Pestana CR; Bonato PS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Nov; 875(1):161-7. PubMed ID: 18514599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder.
    Schröder A; Levin RM; Kogan BA; Das AK; Kay F; Mahashabde A
    Urology; 2000 Dec; 56(6):1063-7. PubMed ID: 11113769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.].
    Merino Salas S
    Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome.
    Sheng Y; Zhang S; Ling J; Hu C; Zhang Z; Lv H
    Pharm Dev Technol; 2022 Apr; 27(4):459-468. PubMed ID: 35575444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New perspectives on the overactive bladder: pharmacokinetics and bioavailability.
    Gupta S; Sathyan G; Mori T
    Urology; 2002 Nov; 60(5 Suppl 1):78-80; discussion 80-1. PubMed ID: 12493362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.].
    Vozmediano-Chicharro R; Blasco Hernández P; Madurga-Patuel B
    Arch Esp Urol; 2017 Jul; 70(6):561-569. PubMed ID: 28678009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration.
    Sathyan G; Jaskowiak J; Evashenk M; Gupta S
    Clin Pharmacokinet; 2005; 44 Suppl 1():7-15. PubMed ID: 16156111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
    Kim T; Kang E; Chun I; Gwak H
    J Pharm Pharmacol; 2008 Jan; 60(1):135-8. PubMed ID: 18088513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of weekly transdermal estradiol controlled delivery system in postmenopausal Chinese.
    Chen GS; Zhang MY; Wang Q; Ye JC
    Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):407-10. PubMed ID: 9863160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.